Enlivex Therapeutics (Israel) Performance
| ENLV Stock | ILA 428.50 28.30 7.07% |
The firm shows a Beta (market volatility) of -0.63, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Enlivex Therapeutics are expected to decrease at a much lower rate. During the bear market, Enlivex Therapeutics is likely to outperform the market. At this point, Enlivex Therapeutics has a negative expected return of -0.006%. Please make sure to confirm Enlivex Therapeutics' jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Enlivex Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enlivex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Enlivex Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 7 M | |
| Total Cashflows From Investing Activities | -38.4 M | |
| Free Cash Flow | -19.2 M |
Enlivex |
Enlivex Therapeutics Relative Risk vs. Return Landscape
If you would invest 45,220 in Enlivex Therapeutics on September 5, 2024 and sell it today you would lose (2,370) from holding Enlivex Therapeutics or give up 5.24% of portfolio value over 90 days. Enlivex Therapeutics is generating negative expected returns and assumes 4.8372% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Enlivex, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Enlivex Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enlivex Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enlivex Therapeutics, and traders can use it to determine the average amount a Enlivex Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENLV |
Estimated Market Risk
| 4.84 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enlivex Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enlivex Therapeutics by adding Enlivex Therapeutics to a well-diversified portfolio.
Enlivex Therapeutics Fundamentals Growth
Enlivex Stock prices reflect investors' perceptions of the future prospects and financial health of Enlivex Therapeutics, and Enlivex Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enlivex Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 147.66 M | |||
| Shares Outstanding | 18.41 M | |||
| Price To Book | 1.23 X | |||
| EBITDA | (18.74 M) | |||
| Cash And Equivalents | 90.6 M | |||
| Cash Per Share | 4.95 X | |||
| Total Debt | 615 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (17.54 M) | |||
| Earnings Per Share | (1.07) X | |||
| Total Asset | 95.15 M | |||
About Enlivex Therapeutics Performance
By analyzing Enlivex Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Enlivex Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enlivex Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enlivex Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.Things to note about Enlivex Therapeutics performance evaluation
Checking the ongoing alerts about Enlivex Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enlivex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enlivex Therapeutics generated a negative expected return over the last 90 days | |
| Enlivex Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (14.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enlivex Therapeutics has accumulated about 90.6 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Roughly 12.0% of the company shares are held by company insiders |
- Analyzing Enlivex Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enlivex Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Enlivex Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enlivex Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enlivex Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enlivex Therapeutics' stock. These opinions can provide insight into Enlivex Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |